ZENVIA receives Nasdaq notification regarding minimum bid price deficiency
SÃO PAULO, Feb. 18, 2026 /PRNewswire/ — Zenvia Inc. (the “Company“) received today a written notice (the “Notice“) from the Listing... Read more.
Genicom to Showcase High-Temperature UV Sensor Solutions at AFPE 2026 in Shanghai
Delivering stable UV measurement in extreme environments up to 250°C with GaN-based technology Strengthening its industrial UV measurement portfolio for global... Read more.
Revel Digital Launches Comprehensive AI Suite for Digital Signage
Six AI-powered capabilities bring natural language content creation, intelligent automation, and real-time network insights to the digital signage industry Revel... Read more.
Strategic Investment Solutions Inc. Data Breach Alert Issued By Wolf Haldenstein
PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION NEW YORK and CHICAGO , Feb. 18, 2026 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf... Read more.
Cardinal Infrastructure Group (CDNL) Announces the Acquisition of A. L. Grading Contractors, Selected Preliminary Estimated Operating Results for 2025, and Updated Consolidated Guidance for 2026
RALEIGH, N.C., Feb. 18, 2026 /PRNewswire/ — Cardinal Infrastructure Group, Inc., (NASDAQ: CDNL) (“Cardinal” or “the Company”) announced... Read more.
Dyson Launches PencilWash™ the Slimmest (1), Ultra-Light, and Hygienic Wet and Dry Cleaner
Engineered for effortless maneuverability and hygienic wet cleaning, the new 38mm PencilWash™ tackles wet spills and stains with a quick drying floor finish Ultra-slim... Read more.
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
With several potential therapies, including Sepiapterin (PTC Therapeutics), NGGT002 (NGGT), JNT-517 (Jnana Therapeutics), Pegvaliase (BioMarin), and others under... Read more.
DERMATOLOGY ASSOCIATES OF CONCORD PROVIDES NOTICE OF DATA SECURITY INCIDENT
February 18, 2026 – Concord, Massachusetts. Dermatology Associates of Concord (“DAC”) is providing notice of an incident that may have impacted the... Read more.
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated... Read more.
Cafrino Gaming Reports Record-Setting 2025 and 64% Year-over-Year Q4 Growth
Cafrino Gaming Delivers Record Revenue and Accelerates B2B Expansion COSTA MESA, Calif., Feb. 18, 2026 /PRNewswire/ — Cafrino Gaming (Cafrino, Inc.), a B2B... Read more.